Cargando…

Population Screening of CHEK2 Mutations in Poland

Detalles Bibliográficos
Autores principales:	Cybulski, Cezary, Huzarski, Tomasz, Huzarska, Jowita, Byrski, Tomasz, Gronwald, Jacek, Oszurek, Oleg, Grajczyk, Jolanta, Sikora, Ligia, Lubiński, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401924/ https://www.ncbi.nlm.nih.gov/pubmed/20223007 http://dx.doi.org/10.1186/1897-4287-4-1-57

Ejemplares similares

Population Screening for Cancer Family Syndromes in the West Pomeranian Region of Poland
por: Gronwald, Jacek, et al.
Publicado: (2006)

The risk of breast cancer in women with a CHEK2 mutation
por: Cybulski, Cezary, et al.
Publicado: (2012)

CHEK2 mutations as markers for high risk of breast cancer
por: Cybulski, Cezary, et al.
Publicado: (2012)

A Lowering of Breast and Ovarian Cancer Risk in Women with a BRCA1 Mutation by Selenium Supplementation of Diet
por: Huzarski, Tomasz, et al.
Publicado: (2006)

Coverage of the Genetic Background of Breast Cancer in the Polish Population
por: Serrano-Fernández, Pablo, et al.
Publicado: (2006)

Association of recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the risk of borderline ovarian tumor
por: Ogrodniczak, Alicja, et al.
Publicado: (2022)

Genetic testing for hereditary breast cancer in Poland: 1998–2022
por: Gronwald, Jacek, et al.
Publicado: (2023)

Hereditary breast and ovarian cancer
por: Gronwald, Jacek, et al.
Publicado: (2008)

Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband
por: Gronwald, J, et al.
Publicado: (2009)

CDH1 gene mutations do not contribute in hereditary diffuse gastric cancer in Poland
por: Jakubowska, Anna, et al.
Publicado: (2010)

Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer
por: Łukomska, Alicja, et al.
Publicado: (2021)

Blood arsenic levels and the risk of familial breast cancer in Poland
por: Marciniak, Wojciech, et al.
Publicado: (2019)

BRCA1 founder mutations compared to ovarian cancer in Belarus
por: Savanevich, Alena, et al.
Publicado: (2014)

Copper as diagnostic marker of cancers
por: Muszyńska, Magdalena, et al.
Publicado: (2015)

Magnesium as a diagnostic marker of cancer
por: Marciniak, Wojciech, et al.
Publicado: (2015)

Iron and breast cancer risk
por: Sukiennicki, Grzegorz, et al.
Publicado: (2012)

Frequency of BRCA1 and BRCA2 mutations in ovarian cancer patients in South-East Poland
por: Jasiewicz, Andrzej, et al.
Publicado: (2022)

Selenium as diagnostic marker of cancers
por: Jaworska-Bieniek, Katarzyna, et al.
Publicado: (2015)

Zinc as diagnostic marker of cancers
por: Kaczmarek, Katarzyna, et al.
Publicado: (2015)

Iron as diagnostic marker of cancer
por: Sukiennicki, Grzegorz, et al.
Publicado: (2015)

Genetic predisposition to male breast cancer in Poland
por: Szwiec, Marek, et al.
Publicado: (2021)

Folic acid and cancer risk in BRCA1 carriers
por: Durda, Katarzyna, et al.
Publicado: (2012)

Pathological complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients
por: Byrski, Tomasz, et al.
Publicado: (2015)

The Prevalence of Founder Mutations among Individuals from Families with Familial Pancreatic Cancer Syndrome
por: Lener, Marcin R., et al.
Publicado: (2017)

Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer
por: Byrski, Tomasz, et al.
Publicado: (2012)

Serum concentration of iron as predictor of cancer risk among BRCA1 mutation carriers
por: Sukiennicki, Grzegorz, et al.
Publicado: (2012)

Serum concentration of selected macro- and microelements and their correlation with the risk of breast and ovarian cancer among BRCA1 mutation carriers
por: Muszyńska, Magdalena, et al.
Publicado: (2012)

Prevalence of Recurrent Mutations Predisposing to Breast Cancer in Early-Onset Breast Cancer Patients from Poland
por: Rogoża-Janiszewska, Emilia, et al.
Publicado: (2020)

Management of ovarian and endometrial cancers in women belonging to HNPCC carrier families: review of the literature and results of cancer risk assessment in Polish HNPCC families
por: Dębniak, Tadeusz, et al.
Publicado: (2015)

Screening with magnetic resonance imaging, mammography and ultrasound in women at average and intermediate risk of breast cancer
por: Huzarski, Tomasz, et al.
Publicado: (2017)

The CHEK 2 GENE mutations and the risk of Gastric cancer
por: Teodorczyk, Urszula, et al.
Publicado: (2012)

Blood Copper Levels and the Occurrence of Colorectal Cancer in Poland
por: Baszuk, Piotr, et al.
Publicado: (2021)

Ovarian cancer risk in Polish BRCA1 mutation carriers is not associated with the prohibitin 3' untranslated region polymorphism
por: Jakubowska, Anna, et al.
Publicado: (2008)

Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers
por: Domagala, Pawel, et al.
Publicado: (2016)

Survival of bladder or renal cancer in patients with CHEK2 mutations
por: Złowocka-Perłowska, Elżbieta, et al.
Publicado: (2021)

HOXB13 mutations and prostate cancer in Poland
por: Kluźniak, Wojciech, et al.
Publicado: (2012)

Serum selenium level and cancer risk: a nested case-control study
por: Narod, Steven A., et al.
Publicado: (2019)

BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update
por: Savanevich, Alena, et al.
Publicado: (2021)

Meeting abstracts from the Annual Conference on Hereditary Cancers 2015: Szczecin, Poland. 24-25 September, 2015
por: Thompson, Ella R., et al.
Publicado: (2017)

Cisplatin in breast cancer treatment in BRCA1 carriers
por: Gronwald, Jacek, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_40ntkks6ho4f3eug4h8q54d1r6